copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
TREMFYA® - cloud. e. janssen. com TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light) TREMFYA® is a prescription medicine used to treat adults and children 6 years and older who also
Rep-Provided SPRAVATO® Resource Rep-Provided SPRAVATO® Resources Janssen has several SPRAVATO® resources that may be helpful to you when communicating with patients or your referral community You may request the following supplementary resources from your SPRAVATO® representative:
Digital and Traditional Media Communications FAQ - Janssen The information in this toolkit is meant to be educational to help inform your communications Your use of these materials is not an endorsement by Johnson Johnson of your treatment center In no event is Johnson Johnson responsible for your use of this material Modifications are prohibited and Johnson Johnson has no liability for any modifications made Your use of this material does
TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp . . . Data illustrates rapid and significant clearance in moderate to severe scalp psoriasis and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory pigmentation at 16 weeks First-of-its-kind study adds to growing body of evidence demonstrating that TREMFYA® is effective for adults with moderate to severe plaque
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other . . . The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC)
OPSYNVI® (macitentan et tadalafil) devient le premier et le seul . . . OPSYNVI® (macitentan et tadalafil) devient le premier et le seul traitement d’association à doses fixes uniquotidien approuvé par Santé Canada pour les patients atteints d’hypertension artérielle pulmonaire (HTAP)
Planning and Hosting Community Engagement Events Planning and Hosting Community Engagement Events Treatment centers are essential to the SPRAVATO® treatment experience You have an opportunity to help educate the local healthcare community and patients about the appropriate use of SPRAVATO® and build awareness of the availability of SPRAVATO® at your treatment center Live or virtual community engagement events can ofer a platform for
| Global Trial Finder Making a Splash for Disease Awareness Making a Splash for Disease Awareness Looking Under the Hood for Green Chemistry Solutions Looking Under the Hood for Green
Oncologia e Hematologia│ Janssen Portugal O cancro afeta milhões de pessoas As nossas soluções inovadoras na Oncologia visam dar qualidade de vida aos doentes e descobrir as curas do amanhã